62 / 70
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 5, September/October 2019
304
AFRICA
4.
Gevers W. Three mutations that cause familial hypercholesterolemia in
Afrikaners identified – a milestone in South African medicine.
S Afr
Med J
1989:
76
: 393–394.
5.
Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinae-
mic states.
Lancet
1969;
7635
: 1380–1382.
6.
Versmissen J, Oosterveer DM, Yazdanpanah M,
et al
. Efficacy of statins
in familial hypercholesterolaemia: a long term cohort study.
Br Med J
2008;
337
: a2423.
7.
Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G,
et
al
. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol
absorption.
Science
2004;
303
: 1201–1204.
8.
Kotze MJ1, van Rensburg SJ. Pathology supported genetic testing and
treatment of cardiovascular disease in middle age for prevention of
Alzheimer’s disease.
Metab Brain Dis
2012;
27
: 255–266.
9.
Humphries SE. Guidelines for the identification and management of
patients with familial hypercholesterolaemia (FH): are we coming to a
consensus?
Atherosclerosis
2011;
12
(suppl): 217–220.
10. Starr B1, Hadfield SG, Hutten BA, Lansberg PJ, Leren TP, Damgaard
D,
et al
. Development of sensitive and specific age- and gender-specific
low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree
relatives with familial hypercholesterolaemia in cascade testing.
Clin
Chem Lab Med
2008;
46
: 791–803.
11. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA,
et
al
. Use of low-density lipoprotein cholesterol gene score to distinguish
patients with polygenic and monogenic familial hypercholesterolaemia:
a case-control study.
Lancet
2013;
38
: 1293–1301.
12. Futema M, Whittall RA, Kiley A, Steel LK, Cooper JA, Badmus E,
et al
; Simon Broome Register Group, Humphries SE. Analysis of the
frequency and spectrum of mutations recognised to cause familial
hypercholesterolaemia in routine clinical practice in a UK specialist
hospital lipid clinic.
Atherosclerosis
2013;
229
: 161–168.
13. Schmidt HH, Hill S, Makariou EV, Feuerstein IM, Dugi KA, Hoeg JM.
Relation of cholesterol-year score to severity of calcific atherosclerosis
and tissue deposition in homozygous familial hypercholesterolemia.
Am
J Cardiol
1996;
77
: 575–580.
14. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordi-
nates LDL catabolism.
J Lipid Res
2009;
50
: S172–S177.
15. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ,
et al
. Reduction in mortality in subjects with homozygous familial
hypercholesterolemia associated with advances in lipid-lowering therapy.
Circulation
2011;
124
: 2202–2207.
16. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC,
et al
. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering
of LDL cholesterol concentrations in patients with homozygous familial
hypercholesterolaemia: a randomised, double-blind, placebo-controlled
trial.
Lancet
2010;
375
: 998–1006.
17. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L,
et al.
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous famil-
ial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-
blind, placebo-controlled trial.
Lancet
2015;
385
: 331–340.
18. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN,
Masana L, Descamps OS,
et al
; European Atherosclerosis Society
Consensus Panel. Familial hypercholesterolaemia is underdiagnosed
and undertreated in the general population: guidance for clinicians to
prevent coronary heart disease: consensus statement of the European
Atherosclerosis Society.
Eur Heart J
2013;
34
: 3478–3490.
19. Klug E; South African Heart Association (SA Heart); Lipid and
Atherosclerosis Society of Southern Africa (LASSA). South African
dyslipidaemia guideline consensus statement.
S Afr Med J
2012;
102
:
178–187.
20. Khine AA, Marais AD. High prevalence of primary dyslipidaemia in
black South African patients at a tertiary hospital in northern Gauteng,
South Africa.
S Afr Med J
2016;
106
(7): 724–729.
21. Futema M, Shah S, Cooper JA, Li K, Whittall RA, Sharifi M,
et al
.
Refinement of variant selection for the LDL cholesterol genetic risk
score in the diagnosis of the polygenic form of clinical familial hyper-
cholesterolemia and replication in samples from 6 countries.
Clin Chem
2015;
61
(1): 231–238.